xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
REDWOOD CITY, Calif., Oct. 24, 2017 -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the Company will report third quarter 2017 financial results and operational highlights on Thursday November 2nd, 2017. OncoMed management will host a conference call and webcast at 4:30 p.m. Eastern Time (ET) / 1:30 p.m. Pacific Time (PT).
Analysts and investors can participate in the conference call by dialing 1-(855) 420-0692 (domestic) and 1-(484) 756-4194 (international) using the conference ID# 4699289. The webcast of the conference call can be accessed live on the Investor Relations section of the OncoMed website, http://www.oncomed.com, and will be available for replay through February 28th, 2018.
An audio replay of the conference call can be accessed by dialing 1-(855) 859-2056 (domestic) or 1-(404) 537-3406 (international) utilizing the conference ID number listed above.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. Navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), rosmantuzumab (anti-RSPO3, OMP-131R10) and anti-TIGIT (OMP-313M32) are part of the company's strategic alliances with Celgene Corporation. OncoMed is independently developing GITRL-Fc (OMP-336B11), as well as continuing to pursue new drug discovery research. The Company is also evaluating potential partnering opportunities for vantictumab (anti-Fzd, OMP-18R5) and ipafricept (Fzd8-Fc, OMP-54F28). For further information about OncoMed Pharmaceuticals, please see www.oncomed.com.
Investor Relations Contact
Peter Rahmer
Trout Group
[email protected]
(646) 378-2973
Mike Zanoni
Trout Group
[email protected]
(646) 378-2924
